The Sanyal Phase 2a in MASLD examined 98 adults with metabolic dysfunction-associated steatotic liver disease and 10 percent liver fat content, randomised to retatrutide or placebo over 48 weeks
Rather than simply suppressing appetite through stimulant effects, GLP-1 medications work with your body's own systems to reduce hunger, slow digestion, and improve how your body processes food
Poor sleep is both a symptom and a contributing factor to depression, so optimizing sleep quality can significantly improve overall well-being
Primary outcome and secondary outcomes After a median duration of follow-up for the whole cohort 2.5 years (interquartile range (IQR), 1.43.6 years), 93 patients (2.6%) in the GLP-1 RAs users group and 319 patients (9.0%) in the GLP-1 RAs non-users group experienced all-cause mortality
Fluctuations in blood sugar levels, hormones tied to appetite, and calorie consumption might shift sleep schedules